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Background/aim: Critically ill patients are at risk of developing gastrointestinal (GI) bleeding due to stress causing mucosal damage.
Aim of the study was to determine the effect of oral/enteral nutrition with or without concomitant pantoprazole on upper GI bleeding
in low risk critically ill patients.
Materials and methods: This was a prospective, randomized, open-label, multicenter study conducted with intensive care unit (ICU)
patients receiving oral/enteral nutritional support. Patients were randomly assigned into two groups including intervention group
(received oral/EN plus pantoprazole) and control group (received only oral/EN).
Results: A total of 300 patients (intervention group: 152, control group: 148) participated in the study. Overall, 226 (75%) patients were
fed by orally and 74 (25%) patients fed by enteral tube feeding. Median duration of nutritional support 4 (range: 2–33) days. Overt upper
GI bleeding was noted only in one patient (0.65%) who was in the intervention group. The overall length of ICU stay of 4 (2–105) days,
while ICU stay was significantly longer in the intervention group than in the control group (P = 0.006).
Conclusions: Our findings seems to indicate that in patients who are at low risk for GI bleeding and under oral/enteral nutritional
support, the use of PPIs may not reduce the risk of bleeding, however these results are imprecise because of low event (GI bleeding) rate
and limited power.
Key words: Critical illness, enteral nutrition, pantoprazole, gastrointestinal bleeding, stress ulcer

1. Introduction
Gastrointestinal (GI) bleeding secondary to stress-related
mucosal lesions are considered likely to be encountered
in critically ill patients as associated with increased risk of
mortality and morbidity in an intensive care unit (ICU).
Mucosal erosions on the gastric luminal surface occur in
approximately 75%–100% of ICU patients within the first
24 h of admission [1,2]. These erosions often cause bleeding
by penetrating the superficial capillaries. Stress-related
GI bleeding occurs in less than 5% of the ICU patients
[3–7]. Enteral nutrition (EN) has been considered to
have protective effects against the bleeding of stress ulcers
by neutralizing the acidic pH level in the gastric lumen
which contributes to structural and functional integrity of

the mucosal surface along with trophic effects on the GI
mucosa [8–10]. There is insufficient evidence regarding
the association between EN and stress ulcer hemorrhage in
critically ill patients, and therefore it becomes challenging
for clinicians to make suggestions. Major risk factors for
stress ulcer hemorrhage are mechanical ventilation (MV),
coagulopathy and burns [3,11]. Proton pump inhibitors
(PPI) and histamine receptor blockers (H2RB) are the
main drugs used for the prophylaxis of stress ulcer related
GI bleeding. Studies have shown that 90% of patients
admitted to ICU receive prophylaxis for stress ulcer related
GI bleeding [12, 13]. However, drugs (H2RB, PPI) used for
prophylaxis against stress ulcer related GI bleeding have
some undesirable effects in critically ill population. These
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drugs, which suppress gastric acid secretion, can cause
hospital-associated pneumonia and Clostridium difficile
enterocolitis [14–16].
Most of previous studies about stress ulcer prophylaxis
belong to 1980s and early 1990s [3,10,11]. Most of the
patients recruited in these studies received nothing
per oral (NPO) and EN was not a widely practiced
nutritional support method by clinicians in those years.
In some studies, use of EN was reported to be associated
with lesser likelihood of less GI bleeding development in
patients with stress ulcers [10,11]. In a limited number
of animal studies, enteral feeding was shown to protect
against stress-related gastric mucosal damage [8,9,17].
Among critically ill adults receiving EN, we have
hypothesized that those patients not treated with
pantoprazole will not have an increased risk of overt GI
bleeding compared to pantoprazole-treated patients.
This study was designed to comparatively evaluate
upper GI bleeding due to stress ulcers in low risk critically
ill patients receiving oral/enteral nutrition support with
or without concomitant pantoprazole therapy.
2. Materials and methods
This multicenter, prospective, controlled, randomized,
open-label trial was performed in five different ICU
clinics between August 2016 and August 2017. Erciyes
University Ethics Committee approved the study (Date of
Approval: 06/05/2016, Protocol No: 2016/289). Written
informed consent was obtained from each patient or
their legal representatives prior to the start of the study.
During the study period, all eligible patients were
screened for inclusion in the study. Patients aged ≥18
years who were expected to stay in ICU for >24 h and had
no contraindications to EN within the first 24 h of ICU
admission were included in the study. Evidence of active
GI bleeding during current hospitalization prior to study
enrollment, presence of coagulopathy (PLT < 50.000/
mm3, INR > 1.5, aPTT > 2 x control), acid suppressing
treatment prior to admission, pregnancy or lactation,
gastric ulcer (history or documented), burns involving
>30% body surface area, head injury or increased
intracranial pressure, partial or complete gastrectomy,
shock, multisystem trauma, exposure to gastric irritant
drugs and lack of informed consent were the exclusion
criteria of the study.
2.1. Randomization
We conducted a randomized, parallel group, multicenter
study. The patients were randomly assigned to receive
oral/enteral nutrition plus pantoprazole (40 mg IV or
oral, ones daily) (Intervention group) or oral/enteral
nutrition alone (Control group). Randomization was
stratified based on the APACHE II scores calculated
before randomization, to enable similar disease severity

in both groups. Randomization was performed by the
research nurse by using previously prepared closed and
opaque envelopes. When there is another patient with
similar APACHE II score, that patient was randomized
to the opposite group with the previous patient.
The selection of the EN formula was at physicians’
discretion, and included Nutrison Diason®, Nutrision
Protein Plus Multi Fiber®, Pulmocare®, Isosource Protein®,
Jevity, Isosource Protein®, Impact Glutamin®, Novasource
GI Control®, Glucerna Select® or Nepro HP®.
Oral supplements were also administered according
to the clinician’s decisions and included Ensure plus
Fiber and Resource Energy.
Initial patient data were collected at the time of
randomization. Demographic data of the patients,
primary complaint for ICU admission, time from ICU
admission to study enrollment and onset of nutritional
therapy were also recorded. APACHE II, modified
NUTRIC score and GCS were calculated within the first
24 h of admission. Nutritional therapy was performed
according to ESPEN and ASPEN critical care nutrition
guidelines [18–20 ]. All patients were screened on a daily
basis for overt and significant GI bleeding. In addition, the
need for invasive or noninvasive MV was also monitored
and recorded on a daily basis. Daily follow-up continued
for each patient until transfer from ICU, occurrence of
any contraindication to oral/enteral nutrition or death.
SOFA score of patients was recorded daily as well as the
length of ICU stay and mortality in the ICU.
2.2. Outcome measures
Primary outcome: Patients were followed from the study
enrolment to the ICU discharge (4 weeks) or the cessation
of EN for possible GI bleeding. Overt GI bleeding was
considered as the presence of coffee ground-like emesis,
hematemesis, melena or hematochezia. Significant GI
bleeding was defined by 3-point decrease in hematocrit
levels within 24 h as accompanied by overt GI bleeding
or by an unexplained 6-point decrease in hematocrit
during a 48-h period [21,22].
Secondary outcomes were daily SOFA scores, length
of ICU stay, length of invasive or noninvasive MV and
ICU mortality rates.
2.3. Statistical analysis
All statistical analyses were made by SPSS 22.0 (IBM
Corp., Armonk, NY, USA). Data are expressed as the
mean ± standard deviation (SD) or the median (lower
and upper quartiles). Comparisons between groups for
continuous variables were performed using the Student
t-Test (normal distribution) or the Mann-Whitney U
test (nonnormal distribution). The χ2 test was used to
analyze categorical variables. A P value of <0.05 was
considered statistically significant.
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3. Results
Of 1516 patients assessed for eligibility, 1216 patients were
excluded and 300 patients who met inclusion criteria were
included in the study, as randomized to intervention (n =
152) and control (n = 148) groups (Figure 1).
Demographic characteristics of patients are provided
in Table 1. The overall age of the patients was 64 ± 18 years.
The most common cause of ICU admission was respiratory
failure and noted in 148 (49%) patients, as followed
by postoperative conditions in 42 (14%) patients and
neurologic disorders in 33 (11%) patients. The APACHE

II score was 19 ± 6 in the overall study population, and
similar between the intervention and control groups (19
± 6 versus 19 ± 6, P > 0.05). First day mean GCS was
13 ± 3. Mean NUTRIC score was 4 ± 2. Baseline mean
hemoglobin value was 10.7 ± 2.2 g/dL, platelet count was
235000±122000/mm3, international normalized value
(INR) was 1.2 ± 0.2 and aPTT was 35 ± 17 s in the overall
study population.
The median time to start oral/enteral nutrition after
admission to the ICU was 6 (1–24) h. The median time
from ICU admission to study enrollment was 14 (1–29)

Figure 1. Flow chart. Enrolled patients are as follows: …….. University Medical ICU: 118 patients, …….. University
Anesthesiology ICU: 26 patients, ………… University Medical ICU: 67 patients, ………. University Pulmonary ICU: 57
patients, Ministry of Health ……………….. Hospital ICU: 32 patients.
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Table 1. Baseline patient characteristics.
Variables

Intervention group
N = 152

Control group
N = 148

P

Age ± SD, years

65 ± 17

63 ± 19

0.484

Sex, n (%)
Male
Female

81 (53)
71 (47)

89 (60)
59 (40)

0.232

APACHE II score ±SD

19 ± 6

19 ± 6

0.686

GCS (First day), ±SD

13 ± 3

12 ± 4

0.260

Modified NUTRIC score ±SD

4±2

4±2

0.991

BMI ± SD

27 ± 6

25 ± 6

0.044

Reason for ICU admission, n (%)
Respiratory failure
Postoperative patients
Neurologic disorders
Sepsis/septic shock
Renal failure (acute/chronic)
Cardiac arrest/other cardiac disorders
Intoxication
Hepatic failure (acute/chronic)
Other

82 (54)
20 (15)
11 (7)
13 (9)
14 (9)
4 (2.6)
3 (2)
1 (0.7)
4 (2.6)

66 (45)
22 (15)
22 (15)
16 (11)
12 (8)
5 (3.4)
2 (1.4)
1 (0.7)
2 (1.4)

Hemoglobin ±SD (g/dL)

10.8 ± 2.2

10.5 ± 2.1

0.277

Platelet counts ±SD

234 ± 125

237 ± 119

0.837

INR ± SD

1.2 ± 0.2

1.2 ± 0.1

0.543

PTT ± SD

36 ± 19

34 ± 15

0.271

Time to study enrolment (range) (h)

14 (2–24)

14 (1–29)

0.043

Time to nutritional intervention (range) (h)

6 (1–24)

5 (1–22)

0.304

Vasopressor therapy, n (%)

4 (2.6)

3 (2.0)

0.729

Noninvasive MV, n (%)

27 (18)

14 (10)

0.036

Invasive MV, n (%)

23 (15)

21 (14)

0.076

Calculated target calorie, ±SD(kcal)

1487 ± 235

1464 ± 233

0.666

Type of nutritional support, n (%)
Oral
Enteral

119 (78)
33 (22)

107 (72)
41 (28)

0.229

0.549

APACHE II: Acute physiology and chronic health evaluation II, GCS: Glasgow coma score, BMI: Body mass
index, ICU: Intensive care unit INR: International normalized ratio, PTT: Partial thromboplastin time, MV:
Mechanical ventilation.

h (Table 1). The mean calculated target calorie of the
patients was 1470 ± 260 kcal/day. Overall, 75% of patients
received oral nutritional supplements (ONS), while EN
was administered via tube feeding (ETF) in 25% of the
patients. ETF was applied by gastric route in 48 (60%) and
by postpyloric route in 32 (40%) patients (Table 1).
Standard oxygen therapy was applied in 63 patients,
while 85 patients required invasive and noninvasive MV.
Noninvasive MV was needed in 14% of the patients and
invasive MV was used in 15% of the patients (Table 1).

Seven (2.3%) patients required vasopressor therapy during
ICU stay. Pantoprazole was given intravenously in 113
(74%) and orally in 39 (26%) patients in the intervention
group. Pantoprazole was started at a median 4 (range 0–24)
h after admission to the ICU. PPI was given to intervention
group during ICU stay. Any patient who can receive PPI
orally received the treatment per oral.
3.1. Outcomes
Primary outcomes: Overt GI bleeding was observed in one
patient in oral/enteral nutrition plus pantoprazole group
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(0.65%). This patient was discharged from the study at the
48th h of the study due to hemodynamic instability. There
was no upper GI bleeding among patients who received
only oral/enteral nutrition (Table 2). The seven-day
hematocrit profile of all patients were as follows; first day:
31.8 ± 6.4, second day: 31.7 ± 6.4, third day: 32.2 ± 6.8,
fourth day: 31.7 ± 6.8, fifth day: 31.8 ± 7.1, sixth day: 30.9
± 6.5 and seventh day: 30.6 ± 5.3. There was no hematocrit
decrease to indicate significant upper GI bleeding in both
groups (Figure 2).
Secondary outcomes: Overall, SOFA scores were 4 (1–2)
on day 1, 3 (1–11) on day 3, 4 (0–13) on day 5 and 4 (2–12)
on day 7. No significant difference was noted between study
groups in terms daily SOFA scores (P > 0.05) (Table 2).
The mean calorie goal reached at the end of 24 h was
1468 ± 292 kcal/day with no significant difference in
amount of calories received by the end 24th h between
study groups (P = 0.562) (Table 2).
The length of nutrition was median 4 (range: 2–33) days
overall, while patients in the intervention group received
significantly longer nutritional support as compared
with control group patients (P = 0.004). Nutritional
intervention was temporarily discontinued in 43 patients
during ICU follow up, while this temporary NPO period
was due to procedures in the ICU in 39 patients and based
on clinician’s decision in 4 patients.
The length of ICU stay was median 4 (range: 2–105)
days in the overall study population, while the intervention
group was associated with significantly longer ICU stay as
compared with the control group patients (P = 0.006).
The duration of invasive MV was 3 (range: 1–30)
days and that of noninvasive MV was 1 (range: 1–6) day,

with no significant difference in duration of invasive and
noninvasive MV between the study groups (P > 0.05).
The ICU mortality rate was 14% and similar between
intervention and control groups.
4. Discussion
This prospective, multicenter, randomized controlled
open-label trial showed that there was no statistical
difference for upper GI bleeding of stress ulcers among
critically ill patients receiving oral/enteral feeding alone
or together with pantoprazole for stress ulcer bleeding
prophylaxis.
Stress ulcer prophylaxis therapy has been routinely
used for the past 3 decades in ICUs. In 1994, Cook et
al. performed a study with 2250 critically ill patients and
concluded coagulopathy and respiratory failure to be
independent risk factors for stress ulcer related upper GI
bleeding [3]. Stress ulcer bleeding prophylaxis has become
almost a routine therapy in these patients preceding this
study.
Gross gastric lesions were reported to be visible within
the first 72 h following the endoscopy procedure in 75%–
100% of critically ill patients [2]. In previous animal and
human studies, EN therapy has been shown to reduce
splanchnic blood flow, GI motility, increase gastric pH levels
and reduce stress-related mucosal related complications
[8,10,17,23,24]. In some studies performed in 1980’s, EN
was reported to be protective against stress ulcer bleeding
in respiratory failure and burn patients. However, being
small scale studies without randomization, these studies
failed to draw adequate attention to stress ulcer bleeding
[10,11]. Currently there are some randomized studies

Table 2. Patient’s primary and secondary outcomes.
Outcomes

Intervention group
N = 152

Control group
N = 148

p

Overt GI bleeding, n (%)

1 (0.65)

0 (0)

-

SOFA scores, (range)
First day
Third day
Fifth day
Seventh day

4.00 (1–12)
3.00 (1–11)
4.00 (0–13)
4.00 (2–12)

3.00 (0–11)
4.00 (2–11)
4.00 (1–11)
4.00 (2–9)

0.824
0.053
0.548
0.865

Amount of calorie received, ±SD(kcal)

1458 ± 317

1478 ± 264

0.562

Duration of nutritional support, days (range)

4 (2–33)

3 (2–12)

0.004

Length of ICU stay, days (range)

5 (2–36)

3 (2–105)

0.006

Duration of invasive MV, days (range)

4 (1–30)

3 (1–9)

0.780

Duration of noninvasive MV, days (range)

1 (1–3)

2 (1–3)

0.275

ICU mortality, n (%)

24 (15)

19 (12)

0.103

GI: Gastrointestinal, MV: Mechanical ventilation, ICU: Intensive care unit.
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Figure 2. Hematocrit profile for the first 7 days in intervention and control groups. Study group patient’s hematocrit
profile (%) (First day: 32.2 ± 7.1, second day: 32.5 ± 7.0, third day: 32.9 ± 6.8, fourth day: 32.6 ± 7.5, fifth day: 32.4 ±
8.1, sixth day: 30.6 ± 7.4 and seventh day: 30.4 ± 6.3). Control group patient’s hematocrit profile (%) (First day: 31.6
± 5.6, second day: 30.7 ± 5.4, third day: 31.0 ± 6.7, fourth day: 30.1 ± 5.3, fifth day: 30.9 ± 4.9, sixth day: 31.5 ± 4.5
and seventh day: 30.9 ± 3.8).

indicated that EN may provide stress ulcer bleeding
prophylaxis. These studies are discussed below.
The effects of early EN on prophylaxis for stress ulcer
related bleeding were investigated in a randomized,
controlled, double blind trial in mechanically ventilated
critically ill patients. These patients were randomized
to either early EN and placebo or EN and intravenous
pantoprazole groups. Both groups were followed for
clinically significant or overt GI bleeding. A total of 102
patients were recruited and 55 patients were given EN plus
pantoprazole, whereas 47 patients received EN and placebo.
Two (1.96%) overt GI bleeding cases were observed during
the study period; one from each group [4].
In another prospective, a double blind, randomized
controlled trial in a mixed ICU where the patients that
received EN and MV were also included in the study,
the benefit and harm associated with the administration
of pantoprazole were evaluated [5]. Intravenous
pantoprazole was administered to the patients in the study
group and placebo was administered to the patients in the
control group. Major outcomes from the study included
clinically significant GI bleeding, VAP and Clostridium
difficile infection whereas the minor outcomes included
overt bleeding and mortality. A total of 214 patients (106
patients in group 1 and 108 patients in group 2) were
enrolled in the study. There was no clinical significant GI
bleeding in either group. There were 9 patients with overt
GI bleeding; 3 (2.8%) patients with overt GI bleeding in
the pantoprazole group and 6 (5.6%) patients in placebo
group [5].
Both of these randomized controlled studies had
similar patient characteristics with the current study.

The main similarity between the studies seems to be the
protective role of EN against stress ulcer related bleeding.
The efficacy and safety of withholding PPIs in critical
ill patients were investigated in a pilot randomized
controlled study by Canadian Critical Care Trials Group
(REVISE study) [25]. The patients were recruited from 10
different ICUs in Canada, Saudi Arabia and Australia. The
study included patients that were mechanically ventilated
for at least 48 h. The study included a total of 91 patients;
49 patients received intravenous pantoprazole and 42
placebo. Upper GI bleeding was observed in 6.1% of
the pantoprazole group and 4.8% of placebo group (P =
1.0). Most patients (89%) did not receive EN during the
first three days of study enrollment. Mean APACHE II
scores were 21 and similar in both groups [25]. The mean
APACHE II score was 19 in our study along with lower GI
bleeding rate, which may be explained by the differences in
critical level of ICU patients.
In another study regarding follow up for potential GI
bleeding among 200 surgical trauma ICU patients (73.5%
were TBI), pharmacologic stress ulcer prophylaxis was
discontinued once EN provided full caloric requirements
for patients requiring MV [6]. Authors noted only one
upper bleeding in the patients receiving full EN [6].
Notably our findings also revealed only one upper GI
bleeding under EN support, while multisystem, TBI and
spinal trauma patients were excluded from the current
study
In our study, patients with a multisystem trauma, TBI,
spinal trauma, burns, refractory shock and coagulopathy
were excluded, while patients with respiratory failure were
included in accordance with study by Cook et al. indicated
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respiratory failure to be an independent risk factor for upper
GI bleeding. Respiratory failure was the primary diagnosis
in 148 (49 %) of our patients and 85 (28%) of them required
invasive or noninvasive MV support. Among the patients,
there was only one patient with upper GI bleeding. Our
study and the abovementioned studies have indicated that
stress ulcer prophylaxis may not be required in critically ill
patients, with respiratory failure without coagulopathy and
refractory shock, receiving oral/enteral nutrition therapy.
The effect of prophylaxis for GI bleeding in the ICU
was studied by Kraig et al. in 3298 adult patients who
were randomly assigned to receive daily, single-bolus,
intravenous pantoprazole (40 mg) or placebo during
their nonselective ICU stay [7]. There was no significant
difference between the pantoprazole group and the placebo
group in mortality rates by 90 days after randomization
(31.1% and 30.4%, respectively). There was no difference in
the secondary outcome of clinically important GI bleeding
in pantoprazole and control groups (2.5%, 4.2%, P = 0.58
respectively). EN was started in 58.2% of the patients in
pantoprazole group and 56.4% in control group, on the
first day of the study. EN rate was 85.8% in pantoprazole
group and 85.3% in control group, on the fifth day of the
study. Their analyses were not stratified according to EN
administration, which could have modified the outcomes.
It was stated that additional data are needed to
determine the clinical effects of prophylaxis for GI bleeding
in the ICU to quantify any protective or harmful effects
attributable to the coadministration of EN in the editorial
for this study [26].
In the current study, ICU stay was significantly longer
in the intervention group than in the control group. Albeit
not significant statistically, a tendency for higher mortality
rate was noted in the intervention group. The reason for
these negative outcomes in intervention group may be
related to the pneumonia and C. difficile infection which
may be caused by pantoprazole. Unfortunately, we did not
record these outcomes in our study. We reported this as a
major limitation of our study.
Oral/enteral nutrition was initiated after median 6 h of
ICU admission and the target calorie goal was reached by

the 24th h in 90% of the patients. This may explain the very
low number of upper GI bleeding cases in our study.
The main limitations of the current study seem to be
the relatively small sample size and lack of data on acquired
pneumonia and C. difficile infection due to unavailability
of related hospital records. This is not a blinded study and
there was no placebo group which might have also affected
the results. We did not perform power analysis to detect
necessary number of the patients before the study, which
is another major limitation.
In conclusion, this multicenter prospective randomized
open-label study evaluated effects of oral/enteral nutrition
plus pantoprazole or oral/enteral nutrition alone, in
critically ill patients with low risk factor for GI bleeding.
Both groups consisted of critically ill patients who were fed
via enteral route. Our findings emphasize the likelihood
of no need for GI bleeding prophylaxis among low risk
critically ill patients receiving oral/enteral nutrition.
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